Table 1.
Characteristics of Children with JIA and JIA-associated Uveitis
| Characteristics | Group | |||
|---|---|---|---|---|
| Median (25th – 75th) unless otherwise specified | Overall (N = 287) | JIA (N = 235) | JIA-U (N = 52) | P-value |
| Demographics | ||||
| Gender, female, N (%) | 205 (71.4 %) | 165 (70.2 %) | 40 (76.9 %) | 0.332 |
| Hispanic, N (%) | 24 (8.4 %) | 16 (6.8 %) | 8 (15.4 %) | 0.043* |
| Race, N (%) | ||||
| Caucasian | 221 (77.0 %) | 183 (77.9 %) | 38 (73.1 %) | 0.459 |
| African American | 36 (12.5 %) | 28 (11.9 %) | 8 (15.4 %) | 0.500 |
| Other | 30 (10.5 %) | 24 (10.2 %) | 6 (11.5 %) | 0.800 |
| Disease Characteristics | ||||
| Age JIA diagnosis (yrs.) | 6.4 (2.9 – 11.7) | 7.7 (3.8 – 12.0) | 2.8 (1.8 – 6.6) | <0.001* |
| Duration of JIA at last study visit (yrs.) | 3.4 (1.8 – 5.9) | 3.1 (1.6 – 5.3) | 5.6 (2.9 – 8.9) | <0.001* |
| Total follow up time (months, mean ± SD) | 15.1 ± 12 | 14.2 ± 11.7 | 18.8 ± 12.7 | 0.012* |
| JIA subtype, N (%) | ||||
| Oligo persistent | 119 (41.1 %) | 80 (34.0 %) | 39 (75.0 %) | < 0.001* |
| Oligo extended | 14 (4.9 %) | 12 (5.1 %) | 2 (3.9 %) | 0.754 |
| Polyarticular RF (−) | 70 (24.4 %) | 63 (26.8 %) | 7 (13.5 %) | 0.049* |
| Polyarticular RF (+) | 13 (4.5 %) | 13 (5.5 %) | 0 (0.0 %) | 0.135 |
| Systemic | 22 (7.7 %) | 22 (9.4 %) | 0 (0.0 %) | 0.038* |
| Psoriatic | 10 (3.5 %) | 10 (4.3 %) | 0 (0.0 % | 0.217 |
| Enthesitis related | 37 (12.9 %) | 33 (14.0 %) | 4 (10.8 %) | 0.260 |
| Undifferentiated | 2 (0.7 %) | 2 (0.9 %) | 0 (0.0 %) | 1.00 |
| Labs, N (%) 1 | ||||
| ANA (+) (n = 286) | 112 (39.3 %) | 84 (35.9 %) | 28 (54.9 %) | 0.017* |
| RF (+) (n = 288) | 26 (9.1 %) | 26 (11.1 %) | 0 (0.0 %) | 0.013* |
| Anti-CCP (+) (n = 285) | 24 (8.5 %) | 24 (10.3 %) | 0 (0.0 %) | 0.020* |
| HLA-B27 (+) (n = 192) | 32 (16.8 %) | 26 (16.3 %) | 6 (18.8 %) | 0.740 |
| Earliest ESR (n = 283) | 16 (6 – 38) | 14.5 (6 – 38) | 22 (8 – 38) | 0.327 |
| Medication Use, N (%) (n = 287) | ||||
| Methotrexate oral | 160 (55.9 %) | 124 (52.8 %) | 36 (70.6 %) | 0.020* |
| Methotrexate injection | 167 (58.4 %) | 129 (54.9 %) | 38 (74.5 %) | 0.010* |
| Infliximab | 38 (13.3 %) | 21 (8.9 %) | 17 (33.3 %) | < 0.001* |
| Etanercept | 48 (17.0 %) | 45 (19.4 %) | 3 (5.9 %) | 0.022* |
| Adalimumab | 64 (22.4 %) | 52 (22.1 %) | 12 (23.5 %) | 0.828 |
| Abatacept | 6 (2.1 %) | 4 (1.7 %) | 2 (3.9 %) | 0.600 |
| Quality of Life Scores (child) a | ||||
| PedsQLb Total | 79.9 (66.5 – 90.2) | 80.3 (66.5 – 90.2) | 78.6 (66.2 – 90.7) | 0.612 |
| PedsQLb Psychosocial | 81.0 (67.2 – 90.3) | 81.9 (69.4 – 90.5) | 76.2 (65.0 – 89.7) | 0.248 |
| CHAQc | 0.25 (0.04 – 0.66) | 0.25 (0.04 – 0.66) | 0.25 (0.04 – 0.88) | 0.690 |
| EYE-Qd | 3.62 (3.38 – 3.82) | 3.68 (3.46 – 3.84) | 3.35 (2.88 - 3.56) | < 0.001* |
| Quality of Life Scores (parent) a | ||||
| PedsQLb Total | 81.7 (66.3 – 90.7) | 81.8 (65.6 – 89.7) | 81.3 (69.2 – 92.5) | 0.679 |
| PedsQLb Psychosocial | 82.5 (67.9 – 92.5) | 81.2 (68.1 – 92.3) | 82.4 (67.1 – 92.6) | 0.933 |
| CHAQc | 0.25 (0.04 – 0.63) | 0.31 (0.06 – 0.67) | 0.15 (0 – 0.49) | 0.091 |
| EYE-Qd | 3.73 (3.48 – 3.86) | 3.75 (3.55 – 3.88) | 3.41 (3.20 – 3.64) | < 0.001* |
aIndicates missing data; *p = <0.05; bPediatric Quality of Life Inventory; cChildhood Health Assessment Questionnaire; dEffects of Youngsters Eyesight on Quality of Life
Chi-square tests, two sample t-tests, non-parametric test (Mann Whitney-U or Kolmogorov-Smirnov test)